Literature DB >> 1743226

Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.

E Rintala1, K Jauhiainen, O Alfthan, E Hansson, H Juusela, K Kanerva, H Korhonen, J Permi, M Sotarauta, T Vaalasti.   

Abstract

Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer. The result was in favour of BCG, as shown by the measurements with complete response (CR), disease-free interval and recurrence rate. CR of 58% with MMC and 40% with BCG were reached in 22 instillation series on carcinoma in situ of 18 patients. Due to side effects, MMC instillations were discontinued in 8.6%, and BCG instillations in 19.6%, respectively. After the 2-year follow-up also 1 case of pulmonary tuberculosis occurred in the BCG group.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1743226     DOI： 10.1159/000471653

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  7 in total

Review 1.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

3.  Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.

Authors:  Stefanie Schmidt; Frank Kunath; Bernadette Coles; Desiree Louise Draeger; Laura-Maria Krabbe; Rick Dersch; Samuel Kilian; Katrin Jensen; Philipp Dahm; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2020-01-08

Review 4.  High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.

Authors:  Rajan Veeratterapillay; Rakesh Heer; Mark I Johnson; Raj Persad; Christian Bach
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

5.  Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).

Authors:  Ying-Hui Jin; Xian-Tao Zeng; Tong-Zu Liu; Zhi-Ming Bai; Zhong-Ling Dou; De-Gang Ding; Zhi-Lu Fan; Ping Han; Yi-Ran Huang; Xing Huang; Ming Li; Xiao-Dong Li; Yi-Ning Li; Xu-Hui Li; Chao-Zhao Liang; Jiu-Min Liu; Hong-Shun Ma; Juan Qi; Jia-Qi Shi; Jian Wang; De-Lin Wang; Zhi-Ping Wang; Yun-Yun Wang; Yong-Bo Wang; Qiang Wei; Hai-Bo Xia; Jin-Chun Xing; Si-Yu Yan; Xue-Pei Zhang; Guo-You Zheng; Nian-Zeng Xing; Da-Lin He; Xing-Huan Wang
Journal:  Mil Med Res       Date:  2022-08-17

6.  Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review.

Authors:  Shang-Jun Jiang; Li-Yin Ye; Fan-Hua Meng
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

7.  Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).

Authors:  Guido Dalbagni; Nicole Benfante; Daniel D Sjoberg; Bernard H Bochner; S Machele Donat; Harry W Herr; Asia S Mc Coy; Alicia J Fahrner; Caitlyn Retinger; Jonathan E Rosenberg; Dean F Bajorin
Journal:  Bladder Cancer       Date:  2017-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.